Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

PHASE3CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

February 1, 2016

Primary Completion Date

May 18, 2023

Study Completion Date

August 15, 2023

Conditions
Melanoma, Ocular
Interventions
COMBINATION_PRODUCT

Melphalan/HDS

Melphalan (3 mg/kg IBW) with Hepatic Device System (HDS)

Trial Locations (24)

3000

Universitair Ziekenhuis Leuven, Leuven

8036

Universitätsklinikum Graz, Graz

8091

UniversitätsSpital Zürich, Zurich

10117

Charité Unversitätsmedizin Berlin Comprehensive Cancer Center, Berlin

14263

Roswell Park Cancer Institute, Buffalo

19107

Thomas Jefferson University, Philadelphia

19380

Stanford University, Palo Alto

20141

Istituto Europeo di Oncologia, Milan

27710

Duke University Medical Center, Durham

28034

Hospital Ramón y Cajal, Madrid

30322

Emory University, Atlanta

33612

Moffitt Cancer Center, Tampa

35043

Universitätsklinikum Giessen und Marburg, Marburg

38163

University of Tennessee Health Science Center, Memphis

43210

Ohio State University James Cancer Center, Columbus

60637

University of Chicago, Chicago

69373

Centre Léon Bérard, Lyon

85719

University of Arizona, Tucson

93053

Universitätsklinikum Regensburg, Regensburg

97080

Universitätsklinikum Würzburg, Würzburg

Unknown

Universitätshautklinik Münster, Münster

08036

Clínic Barcelona, Barcelona

SO16 6YD

University Hospital Southampton NHS Trust, Southampton

L9 7AL

Aintree University Hospital, Liverpool

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

IQVIA Biotech

INDUSTRY

lead

Delcath Systems Inc.

INDUSTRY